Showing 281 - 300 results of 326 for search 'Drugs in the United States', query time: 0.08s Refine Results
  1. 281
  2. 282
  3. 283
  4. 284
  5. 285
  6. 286
  7. 287
  8. 288
  9. 289

    Extraction-Free, Direct Determination of Caffeine in Microliter Volumes of Beverages by Thermal Desorption-Gas Chromatography Mass Spectrometry by Xianglu Peng, Melanie Brown, Paul Bowdler, Kevin C. Honeychurch

    Published 2020-01-01
    “…A 5 μL aliquot was introduced to the thermal desorption unit, dried, and thermally desorbed to the GC/MS. …”
    Get full text
    Article
  10. 290

    Potentially commercializable nerve guidance conduits for peripheral nerve injury: Past, present, and future by Chundi Liu, Mouyuan Sun, Lining Lin, Yaxian Luo, Lianjie Peng, Jingyu Zhang, Tao Qiu, Zhichao Liu, Jun Yin, Mengfei Yu

    Published 2025-04-01
    “…To enhance comprehension of clinical situations, this article provides a comprehensive analysis of the clinical efficacy of nerve conduits approved by the United States Food and Drug Administration. It proposes that the initial six months post-transplantation is a critical window period for evaluating their efficacy. …”
    Get full text
    Article
  11. 291
  12. 292

    Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

    Published 2025-02-01
    “…The KEYNOTE 158 trial supported United States Food and Drug Administration (FDA) approval of the Foundation Medicine test (FoundationOneCDx) at TMB≥10 mut/Mb as a companion diagnostic (CDx) for single-agent pembrolizumab in second+line. …”
    Get full text
    Article
  13. 293
  14. 294
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299
  20. 300

    Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain by Jordi Antón, Estefania Moreno Ruzafa, Mireia Lopez Corbeto, Rosa Bou, Judith Sánchez Manubens, Sonia Carriquí Arenas, Joan Calzada Hernández, Violetta Bittermann, Carolina Estepa Guillén, Juan Mosquera Angarita, Lucía Rodríguez Díez, Estíbaliz Iglesias, Miguel Marti Masanet, Berta Lopez Montesinos, Maria I. González Fernández, Alfonso de Lossada, Carmen Peral, Mónica Valderrama, Noelia Llevat, María Montoro Álvarez, Immaculada Calvo Penadés

    Published 2023-12-01
    “…**Methods:** Children were enrolled in this 24-month observational, multicentric, cross-sectional, retrospective study (N = 107) if they had been treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs), had participated in a previous study (ITACA), and continued to be followed up at pediatric rheumatology units at 3 tertiary Spanish hospitals. …”
    Get full text
    Article